4. Issues of Ethnopharmacology in HIV Management
Genotypic Tropism Assays
Genotypic assays evaluate the HIV Env sequence by either reverse-transcription polymerase chain reaction (RT-PCR) sequencing or heteroduplex analysis (HDA). At least 1 genotypic tropism assay is available on the US market. Compared with results of the Trofile® assay, however, the results of genotypic assays have been reported to be inferior in predicting response to maraviroc therapy and agreed with the results of the phenotypic assay only 70% of the time. Other genotypic assays using different techniques are being developed; when available, these should provide lower-cost alternatives to the phenotypic assay. [Wilkin 2010]
Several algorithms that interpret genotype findings to predict a patient’s viral tropism are available, but investigators and clinicians remain divided about whether such algorithms are sufficiently reliable for clinical use. [Recordon-Pinson 2009, McGovern 2010a, McGovern 2010b]
When to Obtain Viral Tropism Tests
Before prescribing maraviroc or any future CCR5 antagonists, clinicians should order viral tropism results. In the United States, the Trofile® assay is the standard tool for obtaining patient tropism profiles, although European practitioners typically use genotypic sequencing. If the tropism assay indicates the presence of only R5 virus, a CCR5 antagonist can be included as part of a combination regimen. If a patient’s viral population contains X4 or dual/mixed virus, clinicians should not prescribe a CCR5 antagonist. The Department of Health and Human Services guidelines on antiretroviral use now also recommend that tropism be assessed when a patient experiences virologic failure on regimen containing a CCR5 antagonist. [DHHS 2011]